Ranbaxy Labs marks 20th year in Ukraine

Indian drug maker has become top player in $3.7 billion market

GURGAON, India — Ranbaxy Labs is celebrating the 20th anniversary of its operations in Ukraine, the Indian generic drug maker said Wednesday.

The drug maker established a base in the eastern European country in 1993 and has since become the largest drug company in the market, whose value is estimated at $3.7 billion, according to the company. Ranbaxy's products in Ukraine include branded and generic drugs.

"Ranbaxy has been providing high-quality, affordable generic medicines to the citizens of Ukraine for the last two decades, thereby supporting the government to bring down healthcare costs," Ranbaxy CEO and managing director Arun Sawhney said. "We remain committed to the Ukraine market and its people and will continue to operate for our paradigm of quality and patients first."

Login or Register to post a comment.